Congress is considering a dangerous government price setting proposal to be included in the budget reconciliation bill known as the “Most Favored Nation” policy. This harmful policy would expand government price setting into Medicaid by tying drug prices to foreign countries, resulting in a giveaway to big hospital systems that will shift costs to patients, employers and taxpayers. This would harm patients and the more than one million U.S. biopharma employees who work tirelessly to research, develop and manufacture lifesaving medicines and treatments. 

What you need to know:

• Foreign reference pricing is a method of setting drug prices based on prices in countries where patients have access to fewer new medicines and often have to wait years to get the medicines they need.

   

• Medicaid patients already pay, on average, 31 cents ($0.31) out-of-pocket for a brand medicine, and this policy would do nothing to lower their costs. However, it would result in fewer medicines for vulnerable populations.

   

• 340B prices are tied to the Medicaid price. This policy would be a giveaway for big hospital systems, allowing them to increase how much they can mark up medicines in 340B, while shifting costs to patients, employers and taxpayers.

   

• U.S. medical innovation would be threatened—putting $100 billion in new investments and thousands of jobs at risk, weakening our global leadership against China and undermining access to lifesaving treatments for American patients.

Make your voice heard. Act now—contact your representative today and urge them to REJECT the “Most Favored Nation” policy.